Jeff Yass’s Regulus Therapeutics RGLS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-150,813
| Closed | -$264K | – | 13560 |
|
|
2025
Q1 | $264K | Buy |
150,813
+114,625
| +317% | +$151K | ﹤0.01% | 10348 |
|
|
2024
Q4 | $57.2K | Buy |
+36,188
| New | +$55.6K | ﹤0.01% | 11624 |
|
|
2024
Q2 | – | Sell |
-22,528
| Closed | -$52.3K | – | 13044 |
|
|
2024
Q1 | $64.9K | Buy |
+22,528
| New | +$36.7K | ﹤0.01% | 11445 |
|
|
2022
Q2 | – | Sell |
-6,583
| Closed | -$16K | – | 13782 |
|
|
2022
Q1 | $20K | Buy |
+6,583
| New | +$17.1K | ﹤0.01% | 12622 |
|
|
2021
Q4 | – | Sell |
-16,416
| Closed | -$73K | – | 13776 |
|
|
2021
Q3 | $113K | Buy |
16,416
+3,887
| +31% | +$28.5K | ﹤0.01% | 11987 |
|
|
2021
Q2 | $102K | Buy |
+12,529
| New | +$140K | ﹤0.01% | 12090 |
|
|
2020
Q3 | – | Sell |
-6,506
| Closed | -$44K | – | 11056 |
|
|
2020
Q2 | $44K | Sell |
6,506
-558
| -8% | -$3.65K | ﹤0.01% | 9783 |
|
|
2020
Q1 | $33K | Buy |
+7,064
| New | +$61.6K | ﹤0.01% | 9804 |
|
|
2019
Q2 | – | Sell |
-1,538
| Closed | -$16K | – | 10734 |
|
|
2019
Q1 | $16K | Buy |
+1,538
| New | +$16.7K | ﹤0.01% | 8619 |
|
|
2018
Q4 | – | Sell |
-2,439
| Closed | -$58K | – | 9809 |
|
|
2018
Q3 | $58K | Buy |
+2,439
| New | +$80.4K | ﹤0.01% | 8802 |
|
|
2018
Q1 | – | Sell |
-272
| Closed | -$34K | – | 10029 |
|
|
2017
Q4 | $34K | Buy |
+272
| New | +$34.4K | ﹤0.01% | 9005 |
|
|
2017
Q3 | – | Sell |
-529
| Closed | -$63K | – | 9490 |
|
|
2017
Q2 | $63K | Buy |
529
+106
| +25% | +$17.7K | ﹤0.01% | 8839 |
|
|
2017
Q1 | $83K | Sell |
423
-225
| -35% | -$42.8K | ﹤0.01% | 8463 |
|
|
2016
Q4 | $175K | Buy |
648
+440
| +212% | +$143K | ﹤0.01% | 8759 |
|
|
2016
Q3 | $82K | Buy |
208
+117
| +129% | +$48.1K | ﹤0.01% | 8009 |
|
|
2016
Q2 | $32K | Sell |
91
-222
| -71% | -$159K | ﹤0.01% | 8315 |
|
|
2016
Q1 | $261K | Sell |
313
-365
| -54% | -$290K | ﹤0.01% | 7489 |
|
|
2015
Q4 | $710K | Sell |
678
-2,508
| -79% | -$2.51M | ﹤0.01% | 6108 |
|
|
2015
Q3 | $2.5M | Buy |
3,186
+2,206
| +225% | +$2.26M | ﹤0.01% | 3847 |
|
|
2015
Q2 | $1.29M | Buy |
980
+752
| +330% | +$1.21M | ﹤0.01% | 5654 |
|
|
2015
Q1 | $463K | Buy |
228
+36
| +19% | +$78.2K | ﹤0.01% | 7237 |
|
|
2014
Q4 | $369K | Buy |
+192
| New | +$341K | ﹤0.01% | 7784 |
|
Other funds holding RGLS
Jeff Yass's RGLS Position: Q2 2025 in Review
Jeff Yass sold out of Regulus Therapeutics (RGLS) in Q2 2025, closing a stake of 150,813 shares — an estimated $264K sold.
Jeff Yass first reported a position in RGLS in Q4 2014 and held it in 22 quarters. The position peaked at $2.5M in Q3 2015. 0 funds tracked by Wall St. Rank hold RGLS as of Q2 2025.
- Jeff Yass reported no remaining Regulus Therapeutics position as of Q2 2025 after selling out during the quarter.
- Jeff Yass sold 150,813 Regulus Therapeutics shares in Q2 2025, an estimated $264K.
- Jeff Yass first reported a position in Regulus Therapeutics in Q4 2014 and held it in 22 quarters.
- Jeff Yass's Regulus Therapeutics position peaked at $2.5M in Q3 2015.
- 0 funds tracked by Wall St. Rank held Regulus Therapeutics as of Q2 2025.
Based on Susquehanna International Group's 13F filing for Q2 2025, filed 14 Aug 2025.